Home › Bronchiolitis Obliterans Syndrome › Michigan
Bronchiolitis Obliterans Syndrome clinical trials in Michigan
7 studies for Bronchiolitis Obliterans Syndrome are looking for participants at sites in Michigan.
Cities in Michigan
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
- University of Michigan, Ann Arbor
- Henry Ford Hospital, Detroit
- Corewell Health Hematology Oncology, Grand Rapids
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT06585774Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
- Corewell Health, Grand Rapids
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05919511A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
- Barbara Ann Karmanos Cancer Institute, Detroit
RecruitingPhase 2
Ages 2 and older · All sexes · Updated Jun 16, 2026 · NCT04710576BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
- University of Michigan, Ann Arbor
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT05922761A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- University of Michigan, Ann Arbor
- Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT06615050Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 18, 2025 · NCT06419439A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Henry Ford Cancer Institute, Detroit
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT06619561From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.